News Focus
News Focus
icon url

Bickema

06/20/14 12:29 PM

#179576 RE: caravon #179574

I figured there wasn't much to take away from the potential deal. After all, as you said, 2-3 Billion is nothing for ABBV.

What I really want to know is what ENTA's plans for their increasingly growing cash position.

I guess it would be smart to conserve capital until first full quarter of sales are in for their lead Hep C drug.